A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.

ABSTRACT:

Background

Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicenter, open-label, single-arm phase II trial that evaluated the efficacy of S-1 and oxaliplatin (SOX) in advanced hepatocellular carcinoma. All patients included in the present study were systemic treatment-naïve. Prior treatment with sorafenib was allowed, but other treatments were not.

Methods

Patients received S-1 (40 mg/m² twice daily from day 1-14) and oxaliplatin (130 mg/m² on day 1) every 3 weeks. The primary end point was time to progression (TTP). Secondary end points included progression-free survival, overall survival (OS), respon

SUBMITTER: Lee DW 

PROVIDER: S-EPMC5838934 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature